Answers are grounded in this paper and cite their sources.
Implant-associated infections call for antimicrobial coatings that combine high efficacy with acceptable cytocompatibility. Here, ZnO nanoparticles (nominal: ~30 nm; 70 ± 40 nm Feret diameter by TEM of the cured film) and Zn2+ ions were co-incorporated into a room-temperature-cured organosiloxane coating at a common nominal total zinc content of 460 ppm (measured by ICP-OES: 554–718 ppm), and the ZnO:Zn2+ molar ratio was varied across five doped formulations (A#–E#) and an undoped control (F#). Antibacterial activity against Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 29213) was measured by the film adhesion method (GB/T 31402) under dark incubation, surface reactive oxygen species (ROS) by DCFH-DA imaging, and cytocompatibility against MC3T3-E1 osteoblasts by CCK-8 (ISO 10993-5). The single-species coatings were complementary rather than equivalent: ZnO-only A# gave 95.05% and 53.36% reductions, and Zn2+-only E# gave 79.32% and 94.66%. The 1:1 formulation C# gave 99.95% and ≥99.60%, exceeding the Bliss-independent additive expectation by 0.97 percentage points for E. coli and by at least 2.09 for S. aureus, and was the only coating whose ROS signal differed significantly from all the others (1.5–2.0× that of A# at half the ZnO-derived zinc). All formulations retained ≥96% osteoblast viability, with no pairwise difference surviving Tukey correction. Neither total zinc content nor mobilized zinc tracked potency, so the ratio—not the dose—controls both activity and strain selectivity. A hypothesis for the interfacial origin of this optimum is stated explicitly as untested.
No takes yet. Share an insight, caveat, or question.
Shao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: